{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T12:18:56Z","timestamp":1793103536788,"version":"4.5.0"},"reference-count":22,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2008,4]]},"DOI":"10.1097\/jcp.0b013e318169d4ce","type":"journal-article","created":{"date-parts":[[2008,3,11]],"date-time":"2008-03-11T03:01:06Z","timestamp":1205204466000},"page":"S20-S28","source":"Crossref","is-referenced-by-count":91,"title":["Four-Week, Double-Blind, Placebo- and Ziprasidone-Controlled Trial of Iloperidone in Patients With Acute Exacerbations of Schizophrenia"],"prefix":"10.1097","volume":"28","author":[{"given":"Andrew J.","family":"Cutler","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amir H.","family":"Kalali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter J.","family":"Weiden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Hamilton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Curt D.","family":"Wolfgang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-4-20210128","doi-asserted-by":"crossref","first-page":"473","DOI":"10.2165\/00023210-200216070-00004","article-title":"Relapse and rehospitalisation rates in patients with schizophrenia: effects of second generation antipsychotics.","volume":"16","author":"Csernansky","year":"2002","journal-title":"CNS Drugs"},{"issue":"suppl 2","key":"R2-4-20210128","doi-asserted-by":"crossref","first-page":"5","DOI":"10.2165\/00023210-200418002-00002","article-title":"Current issues in schizophrenia: overview of patient acceptability, functioning capacity and quality of life.","volume":"18","author":"Lambert","year":"2004","journal-title":"CNS Drugs"},{"key":"R3-4-20210128","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1517\/14656566.7.13.1739","article-title":"A review of atypical antipsychotic drugs versus conventional medication in schizophrenia.","volume":"7","author":"Luft","year":"2006","journal-title":"Expert Opin Pharmacother"},{"key":"R4-4-20210128","doi-asserted-by":"crossref","first-page":"389","DOI":"10.2165\/00023210-200620050-00004","article-title":"Mechanism of action of atypical antipsychotic drugs and the neurobiology of schizophrenia.","volume":"20","author":"Horacek","year":"2006","journal-title":"CNS Drugs"},{"key":"R5-4-20210128","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1056\/NEJMoa051688","article-title":"Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.","volume":"353","author":"Lieberman","year":"2005","journal-title":"N Engl J Med"},{"key":"R6-4-20210128","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1176\/appi.ajp.162.9.1621","article-title":"Psychiatric comorbidity in adult attention deficit hyperactivity disorder: findings from multiplex families.","volume":"162","author":"McGough","year":"2005","journal-title":"Am J Psychiatry"},{"key":"R7-4-20210128","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1016\/S0024-3205(03)00419-3","article-title":"Functional characterization of the novel antipsychotic iloperidone at human D2, D3, alpha 2C, 5-HT6, and 5-HT1A receptors.","volume":"73","author":"Kalkman","year":"2003","journal-title":"Life Sci"},{"key":"R8-4-20210128","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1016\/S0893-133X(01)00285-8","article-title":"Extended radioligand binding profile of iloperidone: a broad spectrum dopamine\/serotonin\/norepinephrine receptor antagonist for the management of psychotic disorders.","volume":"25","author":"Kalkman","year":"2001","journal-title":"Neuropsychopharmacology"},{"key":"R9-4-20210128","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0024-3205(00)00911-5","article-title":"Binding of antipsychotic drugs to human brain receptors focus on newer generation compounds.","volume":"68","author":"Richelson","year":"2000","journal-title":"Life Sci"},{"issue":"suppl 4","key":"R10-4-20210128","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1007\/PL00014190","article-title":"Relationship between dopaminergic and serotonergic neuronal activity in the frontal cortex and the action of typical and atypical antipsychotic drugs.","volume":"249","author":"Ichikawa","year":"1999","journal-title":"Eur Arch Psychiatry Clin Neurosci"},{"key":"R11-4-20210128","doi-asserted-by":"crossref","first-page":"2935","DOI":"10.1517\/13543784.9.12.2935","article-title":"An assessment of iloperidone for the treatment of schizophrenia.","volume":"9","author":"Jain","year":"2000","journal-title":"Expert Opin Investig Drugs"},{"key":"R14-4-20210128","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1093\/schbul\/13.2.261","article-title":"The positive and negative syndrome scale (PANSS) for schizophrenia.","volume":"13","author":"Kay","year":"1987","journal-title":"Schizophr Bull"},{"key":"R16-4-20210128","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.schres.2005.02.013","article-title":"Manual for the Extrapyramidal Symptom Rating Scale (ESRS).","volume":"76","author":"Chouinard","year":"2005","journal-title":"Schizophr Res"},{"key":"R17-4-20210128","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/0920-9964(90)90005-R","article-title":"A depression rating scale for schizophrenics.","volume":"3","author":"Addington","year":"1990","journal-title":"Schizophr Res"},{"key":"R18-4-20210128","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1192\/bjp.154.5.672","article-title":"A rating scale for drug-induced akathisia.","volume":"154","author":"Barnes","year":"1989","journal-title":"Br J Psychiatry"},{"issue":"suppl 1","key":"R19-4-20210128","first-page":"12","article-title":"Discontinuing and switching antipsychotic medications: understanding the CATIE schizophrenia trial.","volume":"68","author":"Weiden","year":"2007","journal-title":"J Clin Psychiatry"},{"issue":"suppl 19","key":"R20-4-20210128","first-page":"40","article-title":"Tolerability of ziprasidone: an expanding perspective.","volume":"64","author":"Daniel","year":"2003","journal-title":"J Clin Psychiatry"},{"key":"R21-4-20210128","doi-asserted-by":"crossref","first-page":"1774","DOI":"10.1176\/appi.ajp.158.11.1774","article-title":"Antipsychotic drugs: prolonged QTc interval, torsade de pointes, and sudden death.","volume":"158","author":"Glassman","year":"2001","journal-title":"Am J Psychiatry"},{"key":"R22-4-20210128","doi-asserted-by":"crossref","first-page":"303","DOI":"10.2165\/00002018-200629040-00002","article-title":"Long-term treatment with atypical antipsychotics and the risk of weight gain: A literature analysis.","volume":"29","author":"Gentile","year":"2006","journal-title":"Drug Saf"},{"key":"R23-4-20210128","doi-asserted-by":"crossref","first-page":"S12","DOI":"10.1097\/JCP.0b013e3181694f5a","article-title":"Safety profile of iloperidone: a pooled analysis of 6-week acute-phase pivotal trials.","volume":"28","author":"Weiden","year":"2008","journal-title":"J Clin Psychopharmacol"},{"key":"R24-4-20210128","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1016\/S0006-3223(02)01867-X","article-title":"Assessing and interpreting treatment effects in longitudinal clinical trials with missing data.","volume":"53","author":"Mallinckrodt","year":"2003","journal-title":"Biol Psychiatry"},{"key":"R25-4-20210128","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1191\/1740774504cn049oa","article-title":"The effect of correlationstructure on treatment contrasts estimated from incomplete clinicaltrial data with likelihood-based repeated measures compared with lastobservation carried forward ANOVA.","volume":"1","author":"Mallinckrodt","year":"2004","journal-title":"Clin Trials"}],"container-title":["Journal of Clinical Psychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/00004714-200804001-00004","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T17:00:35Z","timestamp":1786035635000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00004714-200804001-00004"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,4]]},"references-count":22,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2008]]}},"URL":"https:\/\/doi.org\/10.1097\/jcp.0b013e318169d4ce","relation":{},"ISSN":["0271-0749"],"issn-type":[{"value":"0271-0749","type":"print"}],"subject":[],"published":{"date-parts":[[2008,4]]}}}